Skip to main content
OpenTrials
Completed

NCT Number: NCT01548937

Serotonin Transporter Density in Late-life Depression With and Without Dementia

This study will recruit a total of 40 evaluable subjects (20 cognitively depressive, and 20 AD depressive); each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping.

Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events.

This study is expected to be completed in a period of 3 years.

Completed

Looking for future studies?

Notify Me

Key information

Age range

50 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

About this study

Depression and dementia are the two common psychiatric disorders in the elder subjects. Alzheimer's disease (AD) is the most frequent cause of dementia and about 20% of them have depression. Depression subjects are associated with more rapid cognitive decline, a poorer response to treatment. Post mortem study showed close relationship between AD and disruptions of the serotonergic system, including loss of serotnergic neurons at brain stem. However, the alternations in presynaptic serotonin function relative to demented or non-demented subjects remain to be investigated in living subjects. In this study, the investigators will collect 40 elder subjects (i.e., age above or equal to 50 years old). The serotonin transporter activity will be compared between subjects with or without dementia using I-123 ADAM images. The single photon emission tomography (SPECT) will be compared to recent (within 6 months) F-18 FDG PET images for further investigation.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients may be enrolled in the AD depressive group if they:
  • Are males or females at least 50 years of age;
  • Fulfilled the DSM-IV criteria for Major depressive disorder (APA, 1994) by MINI interview.
  • Meet the NINCDS/ADRDA(National institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association) criteria for probable AD
  • A Mini Mental State Examination (MMSE) score at screening between 10 and 24 inclusive;
  • Give informed consent. If the patient is incapable of giving informed consent, the caregiver may consent on behalf of the patient (the patient must still confirm assent).
  • Patients may be enrolled in the cognitively depressive group if they:
  • Are males or females at least 50 years of age;
  • Fulfilled the DSM-IV criteria for Major depressive disorder (APA, 1994) by MINI interview.
  • Memory function above the lower normal limits (i.e. 1.5 SD above the mean) on tests for episodic memory.
  • Clinical Dementia Rating = 0. Memory Box score must be 0.
  • Cognitively normal, based on an absence of significant impairment in cognitive functions or ADL.
  • A MMSE score at screening > 24 for those with education level of 6 years or above and > 17 for those are illiterate;
  • Give informed consent.

Exclusion criteria

  • Pregnant or becoming pregnant during the study (as documented by pregnancy testing at screening or at any date during the study according to the PI discretion) or current breast feeding.
  • Conditions affecting brain structure or function (e.g., stroke, diabetes, head trauma, depression) or use of cognitively
  • Substance abuse.
  • Alcohol dependence

Treatment and study plan

I-123 ADAM

Drug

This study will recruit a total of 40 evaluable subjects (20 cognitively depressive, and 20 AD depressive), Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping.

Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events.

Primary outcomes

  1. Evaluate the differences of serotonin transporter activity among depressive patient with or without dementia.

    Time frame: three years

    To expand the database of I-123 ADAM SPECT imaging in AD depressive and cognitively depressive patients to refine the definition of a positive scan in patient with AD and MDD.

Secondary outcomes

  1. Evaluate the relationship between the serotonin transporter activity and F-18 FDG PET image patter.

    Time frame: three years

    To expand the safety database of I-123 ADAM SPECT imaging Safety variables include adverse event count, lab parameters, vital signs, and ECG. Comparison will be generally made to baseline, as appropriate.

Sponsors and collaborators

Lead sponsor

Chang Gung Memorial Hospital

Other

Registry information

Important dates

Study start
2010
Primary completion
2012
Study completion
2012
First posted
Mar 8, 2012
Registry last updated
Jan 28, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.